The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination synergy of spliceosome modulator ADC with a K-Ras inhibitor in K-Ras–mutated pancreatic cancers.
 
Satyajit Mitra
Employment - Akari Therapeutics; Peak Bio, Inc.
Leadership - Peak Bio, Inc.
Stock and Other Ownership Interests - Akari Therapeutics
Research Funding - Akari Therapeutics (Inst); Peak Bio Inc (Inst)
Patents, Royalties, Other Intellectual Property - Patent application PCT/US2024/024997 and US provisional patents 63/882,631; 63/891,856; 63/891,861 and 63/958,508 were filed in the last 24 months. Above IP filings are property of Peak Bio, Inc, a subsidiary of Akari Therapeutics, Plc. (Inst)
Travel, Accommodations, Expenses - Akari Therapeutics; Peak Bio Inc
 
Mastewal Abuhay
Employment - Akari Therapeutics
Stock and Other Ownership Interests - Akari Therapeutics
Research Funding - Akari Therapeutics
Patents, Royalties, Other Intellectual Property - Akari Therapeutics, Kenjockety Biotechnology
 
Howard Stern
Employment - TigaTx
Leadership - TigaTx
Stock and Other Ownership Interests - TigaTx
Consulting or Advisory Role - Akari Therapeutics and TigaTx
Patents, Royalties, Other Intellectual Property - Genentech, Infinity Pharmaceuticals, Juno Therapeutics, TigaTx